Product list
Varifarma Products
58 products with active ingredients, strengths, pack sizes and therapeutic uses. Search or filter the list below.
Showing 58 of 58 products
| Enquire | ||||||
|---|---|---|---|---|---|---|
| 1 | Anastrozol VarifarmaOral | Anastrozole | 1 mg | Tablets; typically 28/30 tablets | Breast cancer; hormone-receptor-positive disease | Enquire |
| 2 | BozatinixOral | Cabozantinib | 20 mg, 40 mg, 60 mg | Tablets; pack size varies by market | Renal cell carcinoma; hepatocellular carcinoma; differentiated thyroid cancer | Enquire |
| 3 | CabazilInjectable | Cabazitaxel | 60 mg/1.5 mL | 1 vial (with solvent/diluent depending on presentation) | Metastatic castration-resistant prostate cancer | Enquire |
| 4 | CanitibOral | Neratinib | 40 mg | 180 tablets commonly used for a 30-day supply | Extended adjuvant treatment of HER2-positive early breast cancer | Enquire |
| 5 | Capecitabina VarifarmaOral | Capecitabine | 150 mg, 500 mg | Tablets; commonly 120 tablets for 500 mg presentation | Colorectal, breast and gastric/GE-junction cancers | Enquire |
| 6 | Carboplatino VarifarmaInjectable | Carboplatin | 150 mg/15 mL, 450 mg/45 mL | 1 vial | Ovarian, lung, head & neck and other solid tumors | Enquire |
| 7 | CiprofarmaOral | Cyproterone | 50 mg | 30 tablets commonly | Androgen-dependent prostate cancer; androgen suppression | Enquire |
| 8 | CPT 11Injectable | Irinotecan | 100 mg/5 mL | 1 vial | Colorectal cancer; other solid tumors in combination regimens | Enquire |
| 9 | Dacarbazina VarifarmaInjectable | Dacarbazine | 200 mg | 1 vial | Metastatic melanoma; Hodgkin lymphoma and other malignancies | Enquire |
| 10 | GefitOral | Gefitinib | 250 mg | 30 tablets commonly | EGFR-mutated non-small-cell lung cancer | Enquire |
| 11 | IxafnibOral | Axitinib | 1 mg, 5 mg | 56 tablets commonly | Advanced renal cell carcinoma | Enquire |
| 12 | KipanibOral | Pazopanib | 200 mg, 400 mg | 30 tablets commonly | Renal cell carcinoma; advanced soft-tissue sarcoma | Enquire |
| 13 | LenvatibOral | Lenvatinib | 4 mg, 10 mg | 30 capsules commonly | Differentiated thyroid cancer; renal cell carcinoma; hepatocellular carcinoma; endometrial cancer in combinations | Enquire |
| 14 | Letrozol VarifarmaOral | Letrozole | 2.5 mg | 30 tablets commonly | Hormone-receptor-positive breast cancer | Enquire |
| 15 | MaximitomInjectable | Mitomycin C | 10 mg, 20 mg | 1 vial | Bladder cancer; GI and other solid tumors; ophthalmic/other specialist uses | Enquire |
| 16 | Paclitaxel VarifarmaInjectable | Paclitaxel | 30 mg/5 mL, 100 mg/16.7 mL, 260 mg/43.4 mL | 1 vial | Ovarian, breast, non-small-cell lung and other cancers | Enquire |
| 17 | RoteronaOral | Abiraterone | 250 mg, 500 mg | Tablets; pack varies by market | Metastatic prostate cancer | Enquire |
| 18 | RupovarOral | Rucaparib | 200 mg, 250 mg, 300 mg | 60 tablets commonly | BRCA-mutated advanced ovarian/fallopian tube/primary peritoneal cancer; prostate cancer in selected settings | Enquire |
| 19 | SuprolOral | Trifluridine/Tipiracil | 15/6.14 mg, 20/8.19 mg | 20 tablets commonly | Metastatic colorectal cancer; metastatic gastric/GE-junction cancer | Enquire |
| 20 | Tamoxifeno VarifarmaOral | Tamoxifen | 10 mg, 20 mg | 30 tablets commonly | Hormone-receptor-positive breast cancer; prevention in selected high-risk patients | Enquire |
| 21 | UltraciclibOral | Palbociclib | 75 mg, 100 mg, 125 mg | 21 capsules/tablets per cycle pack commonly | HR-positive/HER2-negative advanced or metastatic breast cancer | Enquire |
| 22 | UnitiobOral | Sunitinib | 12.5 mg, 25 mg, 37.5 mg, 50 mg | 28 capsules/tablets commonly | Renal cell carcinoma; GIST; pancreatic neuroendocrine tumors | Enquire |
| 23 | VarigestrolOral | Megestrol | 40 mg, 160 mg | Tablets; pack varies | Advanced endometrial or breast cancer; appetite/cachexia management in selected settings | Enquire |
| 24 | VaxemesOral | Exemestane | 25 mg | 30 tablets commonly | Hormone-receptor-positive breast cancer | Enquire |
| 25 | VarizolomidaOral | Temozolomide | 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg | 5 or 20 capsules/tablets depending on strength/market | Glioblastoma and anaplastic astrocytoma | Enquire |
| 26 | BendavarInjectable | Bendamustine | 100 mg | 1 vial | Chronic lymphocytic leukemia; indolent B-cell non-Hodgkin lymphoma | Enquire |
| 27 | BinapOral | Ibrutinib | 140 mg, 280 mg, 420 mg, 560 mg | 28 capsules/tablets commonly | CLL/SLL, mantle cell lymphoma, Waldenström macroglobulinemia and other B-cell malignancies | Enquire |
| 28 | CelazaInjectable | Azacitidine | 100 mg | 1 vial | Myelodysplastic syndromes; acute myeloid leukemia | Enquire |
| 29 | CistadineInjectable | Clofarabine | 1 mg/mL (20 mL vial = 20 mg) | 1 vial | Relapsed/refractory acute lymphoblastic leukemia in pediatric patients | Enquire |
| 30 | DeygluxOral | Eliglustat | 84 mg | 60 capsules commonly | Gaucher disease type 1 | Enquire |
| 31 | DricaleuInjectable | Cladribine | 10 mg/mL | 1 vial | Hairy cell leukemia; selected hematologic malignancies | Enquire |
| 32 | FostaxOral | Fostamatinib | 100 mg, 150 mg | 60 tablets commonly | Chronic immune thrombocytopenia in adults with insufficient response to prior treatment | Enquire |
| 33 | Hidroxiurea VarifarmaOral | Hydroxyurea | 500 mg | 100 capsules/tablets commonly | Myeloproliferative disorders; sickle cell disease | Enquire |
| 34 | Idarubicina VarifarmaInjectable | Idarubicin | 5 mg, 10 mg | 1 vial | Acute myeloid leukemia; selected acute leukemias | Enquire |
| 35 | LeunibOral | Dasatinib | 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg | 30 tablets commonly | Philadelphia chromosome-positive CML; Ph+ ALL | Enquire |
| 36 | LinotaxOral | Nilotinib | 150 mg, 200 mg | 112 capsules commonly (4-week supply) | Philadelphia chromosome-positive CML | Enquire |
| 37 | MaxidaunoInjectable | Daunorubicin | 20 mg | 1 vial | Acute myeloid/lymphoblastic leukemia; other hematologic malignancies | Enquire |
| 38 | NIBCLUSOral | Ponatinib | 15 mg, 30 mg, 45 mg | 30 tablets commonly | Ph+ CML and Ph+ ALL, including T315I mutation | Enquire |
| 39 | VarimerOral | Mercaptopurine | 50 mg | 25/50/100 tablets depending on market | Acute lymphoblastic leukemia; maintenance therapy | Enquire |
| 40 | VarimesnaInjectable & oral | Mesna | 100 mg/mL injection; 400 mg/1000 mg tablets in some markets | Injection vial/ampoule; oral pack varies | Prevention of urotoxicity from ifosfamide and selected oxazaphosphorines | Enquire |
| 41 | VaritrinoxInjectable | Arsenic trioxide | 1 mg/mL (10 mg/10 mL) | 1 vial | Acute promyelocytic leukemia | Enquire |
| 42 | VaridronicoInjectable | Zoledronic acid | 4 mg/5 mL | 1 vial | Cancer-related hypercalcemia; prevention/treatment of skeletal complications from bone metastases | Enquire |
| 43 | Busulfan VarifarmaInjectable | Busulfan | 6 mg/mL | 10 mL vial | Conditioning before hematopoietic stem-cell transplantation | Enquire |
| 44 | CelixaforInjectable | Plerixafor | 20 mg/mL (24 mg/1.2 mL) | 1 vial | Stem-cell mobilization for autologous transplantation | Enquire |
| 45 | PhelinumInjectable | Melphalan | 50 mg | 1 vial | Multiple myeloma; conditioning for hematopoietic stem-cell transplantation | Enquire |
| 46 | TepadinaInjectable | Thiotepa | 15 mg | 1 vial | Conditioning for hematopoietic stem-cell transplantation; selected cancers | Enquire |
| 47 | Tepadina 400 mgInjectable | Thiotepa | 400 mg | 1 vial | Conditioning for hematopoietic stem-cell transplantation; selected cancers | Enquire |
| 48 | Posaconazol VarifarmaInjectable & oral | Posaconazole | 40 mg/mL oral suspension; 100 mg gastro-resistant tablet; 300 mg injection | Pack varies by formulation | Antifungal prophylaxis/treatment in high-risk immunocompromised patients | Enquire |
| 49 | AnfonaxInjectable | Liposomal Amphotericin B | 50 mg/vial | 1 vial | Invasive fungal infections; visceral leishmaniasis | Enquire |
| 50 | BocipalOral | Relugolix | 40 mg | 30 tablets commonly | Advanced prostate cancer; androgen-deprivation therapy | Enquire |
| 51 | MacynOral | Macitentan | 10 mg | 30 tablets commonly | Pulmonary arterial hypertension | Enquire |
| 52 | RipulatOral | Riociguat | 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg | 42 tablets commonly (titration pack) | Pulmonary arterial hypertension; chronic thromboembolic pulmonary hypertension | Enquire |
| 53 | SustengoOral | Tadalafil | 20 mg | 60 tablets commonly; market dependent | Pulmonary arterial hypertension; benign prostatic hyperplasia/erectile dysfunction depending on product/indication | Enquire |
| 54 | HipularInjectable | Treprostinil | 1 mg/mL, 2.5 mg/mL, 5 mg/mL, 10 mg/mL | Vial/cartridge; pack varies | Pulmonary arterial hypertension | Enquire |
| 55 | VadroxOral | Roxadustat | 20 mg, 50 mg, 70 mg, 100 mg, 150 mg | Tablets; pack varies by market | Anemia associated with chronic kidney disease | Enquire |
| 56 | JanvaxOral | Tofacitinib | 5 mg, 10 mg, 11 mg extended-release | 56 tablets commonly | Rheumatoid arthritis; psoriatic arthritis; ulcerative colitis | Enquire |
| 57 | FunomidOral | Teriflunomide | 7 mg, 14 mg | 28 tablets commonly | Relapsing forms of multiple sclerosis | Enquire |
| 58 | EmulimodOral | Fingolimod | 0.5 mg | 28 capsules commonly | Relapsing forms of multiple sclerosis | Enquire |
No products match your search. Ask us about a product — our range is growing.
This list is provided for healthcare professionals and institutional buyers for information only. Strengths, pack sizes and indications are indicative and may vary by market. Availability in Pakistan is subject to DRAP registration, licensing and supply arrangements — please contact us to confirm.
Enquire about a product
Send us the product, strength and quantity you need and we will confirm availability and supply options.
